The International Scientific Advisory Board meets every 18 months and is composed of 11 eminent international scientists whose task is to review clinical and research activities, provide guidelines and promote exchanges with other national and international institutions.   

Charmain
Prof. Roberto ORECCHIA, IEO Scientific Director

Members:

Prof. Anton BERNS, Amsterdam, Holland     

Prof Peter BOYLE, Lyon, France 

Dr. Otis BRAWLEY, Atlanta, GA, USA  

Dr. Carlo CROCE, Columbus, OH, USA 

Prof. Giulio DRAETTA, Houston, TX, USA

Prof. Silvia FRANCESCHI, Aviano, Italy

Prof. Dieter HOELZER, Frankfurt, Germany 

Prof. Robert MILLER, Jacksonville, FL, USA               

Prof. Ulrik RINGBORG, Stockholm, Sweden

Prof. Alphonse TAGHIAN, Boston, MA, USA  

Dr. Andrew VON ESCHENBACH, Montgomery, TX, USA   

Ex officio (statute IEO- art. 18 and 20):

Dr. Fabrizio MASTRILLI, IEO Chief Medical Officer                                                                                 

Extra members:

Prof. Nandita DE SOUZA, London, England

Prof. Andrew LISTER, London, UK

Prof. Martine J. PICCART, Brussels, Belgium

Prof. Arnie PURUSHOTHAM, London, England

Prof. Irene VIRGOLINI, Innsbruck, Austria

The Recruitment and Career Development Advisory Board has the task of advising the Department of Experimental Oncology of IEO on the scientific achievements of the Untenured Faculty Members of the Department upon tenure track review.

Members

Dr. Anton BERNS, Nederlands Kanker Instituut, Amsterdam

Dr. Kristian HELIN, Biotech Research & Innovation Centre, Copenhagen

Dr. David LIVINGSTON, Dana Farber Cancer Institute, Boston

Dr. Tom MISTELI, U.S. National Institutes of Health, Bethesda

Dr. Yossi YARDEN, Weizmann Institute of Science, Rehovot

TTFactor's Business Development Advisory Board is composed of accomplished leaders from the healthcare industry and venture capital who bring their experience in science, medicine, business and finance to prioritize TTFactor's patent portfolio and foster its commercial exploitation. This team of experts has been created to serve scientists and ensure both Institutes that their intellectual properties are valued in accordance with fair principles, that means on the basis of their impact on patient’s care and their ability to become commercial products attractive for the industry.

Members

Giulio DRAETTA, Director, MD Anderson Institute for Applied Cancer Science

Isaac KOHLBERG, Senior Associate Provost and Chief Technology Development Officer at Harvard University

Nagesh MAHANTAPPA, CEO & President at Scholar Rock LLC

Kazumi SHIOSAKI, Managing Partner at MPM Capital, Venture Capitalist

Katherine TURNER, Senior Vice President, Research at Scholar Rock LLC